Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.24
-0.52 (-6.70%)
Feb 10, 2026, 2:14 PM HKT
Market Cap1.40B -2.0%
Revenue (ttm)163.65M
Net Income-85.51M
EPS-0.44
Shares Out193.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,600
Average Volume6,400
Open7.10
Previous Close7.76
Day's Range6.74 - 7.24
52-Week Range4.00 - 8.35
Beta-1.19
RSI29.95
Earnings DateMar 27, 2026

About Wuhan YZY Biopharma

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 106
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2496
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements